hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: in-silico and in-vitro study
Oncology Research · 2024
DOI: 10.32604/or.2024.051569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Mahdi Abdoli Shadbad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Glioblastoma, MicroRNAs, MAP Kinase Signaling System, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Glioblastoma remains a highly invasive primary brain malignancy with an undesirable prognosis. Growing evidence has shed light on the importance of microRNAs (miRs), as small non-coding RNAs, in tumor development and progression. The present study leverages the in-silico and in-vitro techniques to investigate the significance of hsa-miR-181a-5p and the underlying hsa-miR-181a-5p-meidated signaling pathway in glioblastoma development.
Methods
Bioinformatic studies were performed on GSE158284, GSE108474 (REMBRANDT study), TCGA-GTEx, CCLE, GeneMANIA, Reactome, WikiPathways, KEGG, miRDB, and microT-CDS to identify the significance of hsa-miR-181a-5p and its underlying target. Afterward, the U373 cell line was selected and transfected with hsa-miR-181a-5p mimics, and the cell viability, clonogenicity, migration, mRNA expression, apoptosis, and cell cycle were studied using the MTT assay, colony formation test, migration assay, qRT-PCR, and flow cytometry respectively. Results: hsa-miR-181a-5p expression is decreased in glioblastoma samples. The in-silico results have shown that hsa-miR-181a-5p could regulate the MAPK pathway by targeting AKT3. The experimental assays have shown that hsa-miR-181a-5p decreases the migration of glioblastoma cells, arrests the cell cycle, and increases the apoptosis rate. Besides downregulating MMP9 and upregulating BAX, hsa-miR-181a-5p downregulates MET, MAP2K1, MAPK1, MAPK3, and AKT3 expression in U373 cells. The in-vitro results were consistent with in-silico results regarding the regulatory effect of hsa-miR-181a-5p on the MAPK pathway, leading to tumor suppression in glioblastoma. Conclusions: hsa-miR-181a-5p inhibits glioblastoma development partially by regulating the signaling factors of the MAPK pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Zitieren
APA
Shadbad, M. A., & Baradaran, B. (2024). hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: in-silico and in-vitro study. Oncology Research. https://doi.org/10.32604/or.2024.051569
Vancouver
Shadbad MA, Baradaran B. hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: in-silico and in-vitro study. Oncology Research. 2024. doi:10.32604/or.2024.051569
BibTeX
@article{Shadbad2024,
author = {Shadbad, Mahdi Abdoli and Baradaran, Behzad},
title = {hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: in-silico and in-vitro study},
journal = {Oncology Research},
year = {2024},
doi = {10.32604/or.2024.051569}
}
EUVIMED